AnatomyDiseasesChemicals and DrugsAnalytical, Diagnostic and Therapeutic Techniques and EquipmentPhenomena and ProcessesHealth Care
EnoxaparinThrombosisVenous ThrombosisAnticoagulantsHeparinCoronary ThrombosisVenous ThromboembolismSinus Thrombosis, IntracranialFibrinolytic AgentsHemorrhageHeparin, Low-Molecular-WeightCarotid Artery ThrombosisFactor XaIntracranial ThrombosisThromboembolismPhlebographyInjections, SubcutaneousBlood CoagulationPartial Thromboplastin TimeTreatment OutcomeNadroparinPlatelet Aggregation InhibitorsSagittal Sinus ThrombosisIntracranial Embolism and ThrombosisThiophenesAntithrombinsAngina, UnstableDalteparinPlatelet Glycoprotein GPIIb-IIIa ComplexMyocardial InfarctionIliac VeinWarfarinThrombophiliaBleeding TimeFibrin Fibrinogen Degradation ProductsFemoral VeinUpper Extremity Deep Vein ThrombosisAspirinDouble-Blind MethodPulmonary EmbolismRecurrenceThrombolytic TherapyProthrombinAngioplasty, Balloon, CoronaryBlood Coagulation TestsProspective StudiesPlatelet AggregationDrug Therapy, CombinationThrombophlebitisPortal VeinThrombin TimeStentsCerebral VeinsPyridonesPostthrombotic SyndromeRisk FactorsTolmetinTime FactorsFactor VAcenocoumarolHemostasisCavernous Sinus ThrombosisPlatelet ActivationIntermittent Pneumatic Compression DevicesBlood PlateletsHirudinsThromboplastinWhole Blood Coagulation TimeFollow-Up StudiesAntiphospholipid SyndromeVena Cava, InferiorIntracranial Hemorrhage, TraumaticTiclopidineHematomaLateral Sinus ThrombosisHirudin TherapyThrombectomyAcute DiseaseFibrinolysisPipecolic Acids
HeparinLovenoxSubcutaneousRivaroxabanVenous ThromboembolismAnticoagulantTreat deep-vein thromProphylaxisProphylacticThromboembolismCancer-associated thrombosisAcuteDoses of enoxaparinDeepLMWHFactor XaAnticoagulationRenal impairmentHaemostasisPreventionAnti-Xa activityEfficacy and safetyInjectionBlood clotsThromboembolicVersusSafety and efficacyThrombolysisClinicalOutpatientsAnticoagulantsTreatmentSubcutaneouslyRiskTrialsElective
Heparin14
  • Background: Enoxaparin, a low-molecular-weight heparin administered to hospitalized patients once or twice daily, has shown efficacy and safety equivalent to unfractionated heparin in the treatment of acute venous thromboembolic disease. (wustl.edu)
  • Although the cost of either enoxaparin regimen is greater than that of unfractionated heparin, the overall cost of care for each of these 3 treatment strategies is unknown. (wustl.edu)
  • Three hundred thirty-nine hospitalized patients with symptomatic lower extremity deep vein thrombosis were randomly assigned to initial therapy with subcutaneous enoxaparin either once (n = 112) or twice (n = 123) daily, or with dose-adjusted intravenous unfractionated heparin (n = 104), followed by, long-term oral anticoagulant therapy. (wustl.edu)
  • Conclusions: There was no significant difference in the overall cost for the 3-month episode of care for patients treated with either enoxaparin or unfractionated heparin. (wustl.edu)
  • Use of enoxaparin, a low-molecular-weight heparin, and unfractionated heparin for the prevention of deep venous thrombosis after elective hip replacement. (northwestern.edu)
  • Could Aspirin Sub for Heparin to Prevent Cancer-Associated Thrombosis? (medpagetoday.com)
  • Comparison of a low molecular weight heparin and unfractionated heparin for the prevention of deep vein thrombosis in patients undergoing abdominal surgery. (keywen.com)
  • Enoxaparin sodium is a biological substance obtained by alkaline depolymerization of heparin benzyl ester derived from porcine intestinal mucosa. (medicines.org.uk)
  • In FREEDOM COVID, patients were randomized to a therapeutic dose of the low-molecular-weight heparin (LMWH) enoxaparin (1 mg/kg every 12 hours), a prophylactic dose of enoxaparin (40 mg once daily), or a therapeutic dose of the direct factor Xa inhibitor apixaban (5 mg every 12 hours). (mdedge.com)
  • Additionally, there was a severe shortage of Enoxaparin sodium on the market due to the significant drop in pricing and the need for Upstream feed Heparin in 2022. (cgn-pharma.de)
  • The mechanism of action of enoxaparin sets it apart from unfractionated heparin (UFH), a different widely used anticoagulant that inhibits both thrombin and Factor Xa. (cgn-pharma.de)
  • What is difference between Heparin and Enoxaparin? (cgn-pharma.de)
  • Although Enoxaparin is derived from Heparin but the primary difference between unfractionated Heparin and Enoxaparin is inhibition of Thrombin (factor-IIa) and factor-Xa. (cgn-pharma.de)
  • Due to its higher bioavailability than heparin, enoxaparin is preferable. (cgn-pharma.de)
Lovenox7
  • Now, many doctors first prescribe enoxaparin sodium (Lovenox), an anticoagulant used to treat deep-vein thrombosis. (medscape.com)
  • 35 who have undergone a cesarean delivery and who will receive thromboprophylaxis with enoxaparin (Lovenox) at the judgment of their physician. (druglib.com)
  • In other product news for Teva, the company simultaneously announced the launch of its generic equivalent of Lovenox (enoxaparin sodium injection) in seven dosage strengths in the United States. (drugdiscoverynews.com)
  • Enoxaparin was originally made by Sanofi-Aventis and marketed under the brand name Lovenox. (indusbusinessjournal.com)
  • Patients undergoing major orthopaedic surgery such as knee replacement are at high risk of VTE, and Lovenox (enoxaparin) is currently recommended as the standard preventive treatment in these and other at-risk patients. (pharmatimes.com)
  • The original version of enoxaparin, Lovenox, was first approved in 1993. (jwatch.org)
  • Enoxaparin is available almost in all EU countries like Germany (Enoxaparin Lovenox), France (Enoxaparin Clexane/Lovenox), United kingdom (Xaparin/ Inhixa), Italy and Spain. (cgn-pharma.de)
Subcutaneous8
  • This study consisted of the evaluation of in vivo anticoagulant and antithrombotic activity of biodegradable nanoparticles of poly (ε-caprolactone) (PCL) with enoxaparin after subcutaneous injection . (bvsalud.org)
  • Subcutaneous enoxaparin encapsulated in PCL nanoparticles (1000 IU/kg) showed a sustained release in vivo for up to 12 hours (Cmax 0.62 IU/mL) a significantly longer period (P enoxaparin (1000 IU/Kg) that disappeared after 9 hours (Cmax 1.50 IU/mL), however with lower anti-Xa activity. (bvsalud.org)
  • After total knee arthroplasty, patients were randomized to oral rivaroxaban 10 mg daily (n = 1,584) versus subcutaneous enoxaparin 30 mg twice daily (n = 1,564). (acc.org)
  • Among patients undergoing total knee arthroplasty, the use of oral rivaroxaban is superior to subcutaneous enoxaparin in the prevention of any DVT, nonfatal PE, or all-cause mortality. (acc.org)
  • In patients at moderate risk of thromboembolism, the recommended dose of enoxaparin sodium is 2,000 IU (20 mg) once daily by subcutaneous (SC) injection. (medicines.org.uk)
  • METHODS: In a double-blind study, were randomly assigned 1711 consecutive patients undergoing surgery for fracture of the upper third of the femur to receive subcutaneous doses of either 2.5 mg of fondaparinux once daily, initiated postoperatively, or 40 mg of enoxaparin once daily, initiated preoperatively, for at least five days. (mcmaster.ca)
  • In a subgroup analysis of the pooled results of the EINSTEIN-DVT and EINSTEIN-PE trials reported in The Lancet Haematology , Prins et al found that the recurrence rate for venous thromboembolism in cancer patients receiving anticoagulant therapy with oral rivaroxaban (Xarelto) was similar to that in those receiving subcutaneous enoxaparin followed by vitamin K antagonist. (ascopost.com)
  • In the two trials, 8,281 patients with deep-vein thrombosis or pulmonary embolism were randomly assigned to receive rivaroxaban at 15 mg twice daily for 21 days followed by 20 mg once daily or standard therapy consisting of subcutaneous enoxaparin at 1.0 mg/kg twice daily and warfarin or acenocoumarol (target INR of 2.0 to 3.0). (ascopost.com)
Rivaroxaban19
  • Apixaban, dabigatran, rivaroxaban, edoxaban, and betrixaban are alternatives to warfarin for prophylaxis or treatment of deep venous thrombosis (DVT) and pulmonary embolism (PE). (medscape.com)
  • The goal of the trial was to evaluate treatment with the direct factor Xa inhibitor rivaroxaban, compared with enoxaparin after total knee arthroplasty. (acc.org)
  • Rivaroxaban would be noninferior to enoxaparin in preventing deep venous thrombosis (DVT). (acc.org)
  • Rivaroxaban was given 6-8 hours after surgery, while enoxaparin was given 12-24 hours after surgery. (acc.org)
  • The mean time from surgery until the study medication was started was 7 hours in the rivaroxaban group and 17 hours in the enoxaparin group. (acc.org)
  • Study drugs were administered for a mean duration of 11.7 days for the rivaroxaban group and 11.0 days for the enoxaparin group. (acc.org)
  • The primary efficacy outcome, any DVT, nonfatal pulmonary embolism (PE), or all-cause mortality at 17 days occurred in 6.9% of the rivaroxaban group versus 10.1% of the enoxaparin group (p = 0.012). (acc.org)
  • Major venous thromboembolism (VTE) was 1.2% versus 2.0% (p = 0.12), death was 0.1% versus 0.2% (p = 0.74), PE was 0.3% versus 0.5% (p = 0.53), and major bleeding was 0.7% versus 0.3% (p = 0.11), respectively, for rivaroxaban versus enoxaparin. (acc.org)
  • Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty (RECORD4): a randomised trial. (acc.org)
  • Publication lists parameter sets to simulate Rivaroxaban, VKA and Enoxaparin (supplementary files). (ebi.ac.uk)
  • This detrimental effect might not occur during VTE treatment using other anticoagulants, such as rivaroxaban or enoxaparin, given their different mechanisms of action within the coagulation network. (ebi.ac.uk)
  • A quantitative systems pharmacology model was developed describing the coagulation network to monitor clotting factor levels under warfarin, enoxaparin, and rivaroxaban treatment. (ebi.ac.uk)
  • Predictions of individual coagulation factor time courses under steady-state warfarin, enoxaparin, and rivaroxaban treatment reflected the suppression of protein C and protein S under warfarin compared to rivaroxaban and enoxaparin. (ebi.ac.uk)
  • This was the message that came from the RECORD3 study, the first Phase III results for Xarelto (rivaroxaban), the investigational oral direct Factor Xa inhibitor, presented at the XXI Congress of the International Society for Thrombosis and Haemostasis in Geneva, Switzerland. (pharmatimes.com)
  • Oral rivaroxaban had efficacy similar to enoxaparin/vitamin K antagonist in preventing recurrence of venous thromboembolism and was associated with a lower rate of major bleeding. (ascopost.com)
  • of these, 354 received rivaroxaban, and 301 received enoxaparin/vitamin K antagonist. (ascopost.com)
  • Among patients with active cancer, recurrent venous thromboembolism was observed in 5% of rivaroxaban patients and 7% of enoxaparin/vitamin K antagonist patients (hazard ratio [HR] = 0.67, 95% confidence interval [CI] = 0.35-1.30). (ascopost.com)
  • The investigators concluded: "In patients with active cancer and venous thromboembolism, rivaroxaban had similar efficacy to prevent recurrence of venous thromboembolism and reduced the number major bleeding events compared with treatment with enoxaparin and a vitamin K antagonist, although there was no difference between groups for clinically relevant bleeding. (ascopost.com)
  • To date, several clinical trials have evaluated the use of extended-duration VTE prophylaxis with enoxaparin, apixaban, rivaroxaban, and betrixaban compared with standard-duration VTE prophylaxis with enoxaparin. (ajmc.com)
Venous Thromboembolism10
Anticoagulant4
  • Enoxaparin is an anticoagulant widely used in the treatment and prophylaxis of deep vein thrombosis (DVT). (bvsalud.org)
  • Methods: A cost minimization analysis of a 3-month, partially blinded, randomized, controlled efficacy and safety trial of anticoagulant therapy for deep vein thrombosis. (wustl.edu)
  • Enoxaparin is an indirect anticoagulant that binds to and amplifies antithrombin III (a serine protease inhibitor), forming a complex that permanently inactivates factor Xa. (cgn-pharma.de)
  • Anticoagulant treatment references Almost all patients with deep venous thrombosis (DVT) are given anticoagulants and in rare cases thrombolytics. (msdmanuals.com)
Treat deep-vein throm1
  • As part of their deal, Gordon Johnston, a former deputy director at the US Food and Drug Administration (USFDA) dealing with generic drugs, gave Valvani inside information about the approval of the generic version of the drug enoxaparin that is used to treat deep vein thrombosis, authorities alleged. (indusbusinessjournal.com)
Prophylaxis2
Prophylactic3
  • The investigators hypothesize that when enoxaparin is dosed by maternal weight and administered twice daily, the anti-factor Xa level would more frequently achieve prophylactic levels when compared to taking a fixed 40 mg of the drug daily. (druglib.com)
  • If there is a need for earlier than 12 hours enoxaparin sodium preoperative prophylactic initiation (e.g. high risk patient waiting for a deferred orthopaedic surgery), the last injection should be administered no later than 12 hours prior to surgery and resumed 12 hours after surgery. (medicines.org.uk)
  • Bleeding Academic Research Consortium major bleeding types 3 and 5 were slightly numerically higher in the group randomized to therapeutic enoxaparin (0.5%) than prophylactic enoxaparin (0.1%) and therapeutic apixaban (0.3%), but the differences between any groups were not significant. (mdedge.com)
Thromboembolism2
  • A strategy that involves stratifying patients by thrombosis risk significantly reduced thromboembolism and death among high-risk outpatients starting treatment for lung and GI cancers. (medscape.com)
  • In patients at high risk of thromboembolism, the recommended dose of enoxaparin sodium is 4,000 IU (40 mg) once daily given by SC injection preferably started 12 hours before surgery. (medicines.org.uk)
Cancer-associated thrombosis3
  • Comparing aspirin with direct oral anticoagulants instead of injectable heparins should be considered for future clinical trials, assuming the confirmation of preliminary data that suggest that these medicines may be safe and effective for varying manifestations of cancer-associated thrombosis . (medpagetoday.com)
  • Emerging data have enhanced our understanding of cancer-associated thrombosis, a major cause of morbidity and mortality in patients with cancer. (oncologynurseadvisor.com)
  • This review will focus on the epidemiology and pathophysiology of cancer-associated thrombosis, risk factors, and new predictive biomarkers for VTE as well as discuss novel prevention and management regimens of VTE in cancer according to published guidelines. (oncologynurseadvisor.com)
Acute2
  • and for the treatment of acute deep vein thrombosis. (drugdiscoverynews.com)
  • 3] Through extensive clinical trials, Enoxaparin has proven its efficacy and safety in various clinical settings, ranging from acute coronary syndromes to extended thromboprophylaxis. (cgn-pharma.de)
Doses of enoxaparin2
  • BOSTON - Missed doses of enoxaparin correlate with increased incidence of deep vein thrombosis. (the-hospitalist.org)
  • Lower doses of enoxaparin and apixaban were used for those with renal impairment, and lower doses of apixaban were employed for elderly patients (≥ 80 years) and those with low body weight (≤ 60 kg). (mdedge.com)
Deep21
LMWH1
  • This is a multi-center, prospective, randomized controlled study to compare the proportion of patients that achieve the desired effect of LMWH (enoxaparin) thromboprophylaxis as measured by peak anti Xa level with weight based twice daily dosing versus standard fixed daily dosing. (druglib.com)
Factor Xa1
  • Enoxaparin enhances the inhibition of factor Xa and thrombin by increasing antithrombin III activity. (medscape.com)
Anticoagulation1
  • Reports of elevated risk of thrombosis associated with coronavirus disease-19 (COVID-19) have led frontline providers to consider the empiric use of therapeutic anticoagulation for hospitalized patients even in the absence of documented or clinically suspected thrombosis. (springer.com)
Renal impairment2
  • However, there appeared to be less post-operative bleeding in desirudin-treated patients with moderate renal impairment compared to enoxaparin-treated patients. (news-medical.net)
  • Patients with renal impairment randomized to desirudin had a 56% reduction in major VTE and a 45% reduction in major bleeding compared with patients randomized to enoxaparin. (news-medical.net)
Haemostasis3
Prevention3
  • 6 The atherosclerotic cardiovascular disease risk estimator is available online and in mobile app format at http://my.americanheart.org/cvrisk calculator and at http://www.cardiosource.org/en/Science-And-Quality/Practice-Guidelines-and-Quality-Standards/2013-Prevention-Guideline-Tools.aspx . (aafp.org)
  • The approval of ELIQUIS gives European orthopedic surgeons a new option in VTE prevention that is more effective than the current standard of care, enoxaparin 40 mg once daily, and importantly, without increasing bleeding. (salesandmarketingnetwork.com)
  • In these trials, ELIQUIS given orally twice daily demonstrated superior efficacy versus enoxaparin 40 mg given once daily by injection in the prevention of VTE in total knee and total hip replacement, and did not increase the risk of bleeding versus enoxaparin. (salesandmarketingnetwork.com)
Anti-Xa activity1
  • Each prefilled syringe contains enoxaparin sodium 4,000 IU anti-Xa activity (equivalent to 40 mg) in 0.4 mL water for injections. (medicines.org.uk)
Efficacy and safety1
Injection5
Blood clots3
  • Enoxaparin prevents and treats blood clots. (rxwiki.com)
  • Enoxaparin is a prescription medication used to prevent and treat blood clots. (rxwiki.com)
  • Enoxaparin can also be taken at home to prevent blood clots in the legs. (rxwiki.com)
Thromboembolic2
  • Enoxaparin prevents DVT, which may lead to PE in patients undergoing surgery who are at risk for thromboembolic complications. (medscape.com)
  • Enoxaparin has gained significant recognition and utilization in the Middle East and North Africa (MENA) region for the management of thromboembolic disorders. (cgn-pharma.de)
Versus1
  • Continuation of therapy beyond that should be based on the risk for recurrent thrombosis versus the risk of major bleeding for each individual patient. (oncologynurseadvisor.com)
Safety and efficacy2
Thrombolysis1
Clinical1
Outpatients2
  • Evolution of untreated calf deepvein thrombosis in high risk symptomatic outpatients: the blind, prospective CALTHRO Study. (medigraphic.com)
  • Enoxaparin for outpatients with COVID-19: 90-day results from the randomised, open-label, parallel-group, multinational, phase III OVID trial. (uzh.ch)
Anticoagulants1
Treatment5
  • Enoxaparin also has been approved for the treatment of DVT and PE. (medscape.com)
  • Cancer and thrombosis: mechanisms and treatment. (nih.gov)
  • In moderate risk patients, enoxaparin sodium treatment should be maintained for a minimal period of 7-10 days whatever the recovery status (e.g. mobility). (medicines.org.uk)
  • Treatment with enoxaparin sodium is prescribed for at least 6 to 14 days whatever the recovery status (e.g. mobility). (medicines.org.uk)
  • To guarantee its optimal application and improve patient care, it is imperative that ongoing physician education programs emphasize the significance of early diagnosis, adequate risk stratification, and prompt beginning of Enoxaparin treatment. (cgn-pharma.de)
Subcutaneously2
  • If you are injecting Enoxaparin at home, you will be injecting it under the skin (subcutaneously). (rxwiki.com)
  • Enoxaparin comes in an injectable form to be injected under the skin (subcutaneously) or directly into a vein (IV). (rxwiki.com)
Risk4
  • Enoxaparin increases your risk of bleeding, and can cause bleeding in the brain, paralysis, and death. (rxwiki.com)
  • Several risk factors for developing venous thrombosis usually coexist in cancer patients including surgery, hospital admissions and immobilization, the presence of an indwelling central catheter, chemotherapy, use of erythropoiesis-stimulating agents (ESAs) and new molecular-targeted therapies such as antiangiogenic agents. (oncologynurseadvisor.com)
  • Major bleeding rates were low and not significantly different between groups - 2% of all patients, 1% in the high-risk enoxaparin group, 2% in the high-risk control group, and 2% in the low-risk group. (medscape.com)
  • Preoperative initiation (2 hours before surgery) of enoxaparin sodium 2,000 IU (20 mg) was proven effective and safe in moderate risk surgery. (medicines.org.uk)
Trials1
  • Enoxaparin for symptomatic COVID-19 managed in the ambulatory setting: An individual patient level analysis of the OVID and ETHIC trials. (uzh.ch)
Elective1
  • The study that generated the data for the post-hoc analysis was a randomized, active-controlled, double-blind trial of desirudin 15 mg BID vs. enoxaparin 40 mg QD in patients undergoing elective total hip replacement surgery. (news-medical.net)